BACKGROUND/AIMS: We compared intravenous and subcutaneous infliximab (IFX) as treatment for inflammatory bowel disease (IBD). METHODS: This retrospective, multicenter, observational study enrolled patients treated with either intravenous or subcutaneous IFX. Sequential parameters were compared at baseline, 6 months, and 12 months following the initiation of treatment with either type of IFX. The primary outcome was the comparison of the IFX trough levels after 12 months of treatment. RESULTS: In total, 183 participants were included in this study. After 6 months, the subcutaneous group exhibited significant differences compared to the intravenous group; in terms of clinical disease activity (0% vs. 15%, P= 0.007) and IFX trough level (21.72 +/- 8.71 mug/mL vs. 7.70 +/- 16.65 mug/mL, P= 0.002). After 12 months, subcutaneous, as compared to intravenous, achieved improved clinical disease activity (0% vs. 15%, P= 0.044) and IFX trough level (20.41 +/- 12.91 mug/mL vs. 7.06 +/- 6.81 mug/mL, P< 0.001). Analyzing the sequential changes compared with baseline data within each group, we observed significant alterations in subcutaneous; 6 months fecal calprotectin (676.3 +/- 976.6 mug/g vs. 253.9 +/- 483.9 mug/g, P= 0.014), 6 months IFX trough level (7.00 +/- 5.67 mug/mL vs. 18.44 +/- 6.34 mug/mL, P= 0.026), and 12 months IFX trough level (7.00 +/- 5.67 mug/mL vs. 21.33 +/- 4.50 mug/mL, P= 0.034). CONCLUSIONS: This study indicates the potential suitability of subcutaneous IFX as an alternative treatment option for IBD.